Skip to content
Vivanza Biosciences logo

Vivanza Biosciences

530057 BSE
Price unavailable

Vivanza Biosciences (VIVANZA) share price was ₹1.50 at the 28 Oct 2026 close; market capitalisation ₹6.04 Cr; P/E (TTM) 12.50; sector Healthcare. The share price fell 25.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 3.9% year on year to ₹9.29 Cr and net profit was ₹0.15 Cr, against ₹0.09 Cr a year earlier (compared with Jun 2025). Promoters held 20.02% of Vivanza Biosciences in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 47/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹1.50 −0.48 −24.24% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹6.04 Cr
P/E (TTM)
12.5
EBITDA
₹80.00 L
Return on Equity
9.05%
Debt to Equity
2
Book Value
₹1.09
EPS (TTM)
₹0.12
52W High
₹2.72
52W Low
₹1.30

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,768.2035.084,24,250 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,670.0087.772,56,708 Cr15.320.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.0072.351,75,312 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.60108.081,18,199 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.0026.281,17,805 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,339.0034.681,11,764 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,364.9032.701,10,265 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Vivanza Biosciences (this company)
—12.506 Cr1.380.00%9.05%15.72%117 Cr0 Cr
Median 8 companies₹1,768.2034.881,18,002 Cr4.720.47%12.98%16.83%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

47 Average
Overall score

Data confidence 100/100

Category scores

Quality Poor 36
Returns, margins, earnings quality 22% weight
Valuation Average 50
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Poor 25
Solvency, leverage, coverage 9% weight
Momentum Poor 17
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Debtor days have improved from 196 to 39.0 days.

Weaknesses

4
  • Promoter holding is low: 20.0%
  • Company has a low return on equity of 2.11% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -27.3%

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
12
Neutral
6
Bullish
1

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
—

Net Income Growth
-157% lower than 3Y

change over 1 year

Cash Flow Change
-3.2%

change over 1 year

EBITDA Margin Change
-118%

change over 1 year Operating margin -0.75% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
9.23
7.62
6.56
4.42
2.44
3
1.5
0.48
8.94
55.36
45.25
6.36
9.29
Expenses
8.64
7.3
6.27
4.56
2.08
2.89
1.37
1.44
8.79
54.75
45.04
6.59
9.36
Operating Profit
0.59
0.32
0.29
-0.14
0.36
0.11
0.13
-0.96
0.15
0.61
0.21
-0.23
-0.07
OPM %
6.39%
4.2%
4.42%
-3.17%
14.75%
3.67%
8.67%
-200%
1.68%
1.1%
0.46%
-3.62%
-0.75%
Other Income
0.01
0.05
0.02
-0.03
0
0
0.01
0.05
0.02
0.01
0.08
0.01
0.37
Interest
0.11
0.11
0.1
0.09
0.09
0.09
0.09
0.08
0.08
0.05
0.09
0.07
0.11
Depreciation
0
0
0
0.01
0
0
0
0
0
0
0
0.01
0.01
PBT
0.49
0.26
0.21
-0.27
0.27
0.02
0.05
-0.99
0.09
0.57
0.2
-0.3
0.18
Tax %
0%
0%
0%
55.56%
0%
0%
0%
1.01%
0%
0%
0%
50%
22.22%
Net Profit
0.49
0.26
0.21
-0.41
0.27
0.02
0.04
-1
0.09
0.56
0.2
-0.45
0.15
EPS (₹)
0.12
0.06
0.05
-0.1
0.07
0
0.01
-0.25
0.02
0.14
0.05
-0.11
0.04
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
3
6
3
10
10
10
18
28
7
116
116
Expenses
0
4
6
3
10
10
10
17
27
8
115
116
Operating Profit
0
0
1
0
0
0
0
1
1
0
1
1
OPM %
—
-9%
9%
-0.8%
-3.6%
0.9%
-0.6%
3.8%
3.9%
-4.9%
0.6%
0.5%
Other Income
0
0
0
0
1
1
1
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0
0
0
0
0
0
0
1
1
-1
1
1
Tax %
0%
0%
13%
0%
0%
42%
0%
17%
21%
2%
27%
—
Net Profit
0
0
0
0
0
0
0
1
1
-1
0
0
EPS (₹)
-0.32
-0.08
0.05
-0.11
-0.05
0.02
0.08
0.15
0.14
-0.17
0.1
0.12
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.19
4
4
4
4
4
4
4
4
4
4
Reserves
0
0
0
-1
-1
-1
-1
0
1
0
0
Borrowings
0
1
1
1
0
0
6
8
5
9
10
Other Liabilities
0
3
5
6
9
5
7
10
10
4
8
Total Liabilities
1
7
10
11
12
8
16
22
20
16
22
Fixed Assets
0
2
2
2
2
2
2
2
2
2
2
CWIP
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
1
5
8
9
10
6
13
20
17
14
20
Total Assets
1
7
10
11
12
8
16
22
20
16
22
Figures in ₹ Crores

Cash Flow

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
-2
0
1
3
-3
2
-1
2
-2
-3
Investing
0
2
0
0
0
0
0
0
0
0
0
Financing
0
0
-1
-1
-3
3
-2
1
-2
2
3
Net Cash Flow
0
0
-1
0
0
0
0
0
0
0
0
Free Cash Flow
0
-2
0
1
3
-3
2
-1
2
-3
-3
CFO/OP
0
668
-15
-4,300
-876
-3,367
-4,117
-124
203
692
-328
Figures in ₹ Crores

Ratios

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
267
287
782
250
231
275
256
151
398
39
Inventory Days
—
215
150
309
38
26
92
55
28
121
11
Days Payable
—
304
319
878
319
154
207
211
116
140
23
Cash Conversion Cycle
—
178
118
213
-32
103
160
99
64
379
27
Working Capital Days
—
332
237
469
109
104
103
50
44
154
7
ROCE %
—
-10%
13%
0%
6%
17%
12%
11%
10%
-3%
6%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vivanza Biosciences insights

56 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

Public73.90%Others6.07%Promot.20.02%As ofSep 2026

Documents

Frequently Asked Questions about Vivanza Biosciences

What does Vivanza Biosciences Ltd do?
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
Where is Vivanza Biosciences Ltd (VIVANZA) listed?
Vivanza Biosciences Ltd trades under code 530057 on the BSE.
Which sector does Vivanza Biosciences Ltd belong to?
Vivanza Biosciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd has a market capitalisation of ₹6.04 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd trades at a PE ratio of 12.50 as of 28 Oct 2026, on earnings per share of ₹0.12, against a book value of ₹1.09 per share.
What is the 52-week high and low of Vivanza Biosciences Ltd?
Over the last 52 weeks Vivanza Biosciences Ltd has traded between ₹1.3 and ₹2.72 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Vivanza Biosciences Ltd?
Vivanza Biosciences Ltd reported a return on equity of 9.05%. Its debt-to-equity ratio is 2.00.

Company Information

Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]

Website vivanzabiosciences.com
Face Value ₹ 1
Shares Outstanding 4,02,43,902

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530057.md for Vivanza Biosciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month